Edition:
United States

NuVasive Inc (NUVA.OQ)

NUVA.OQ on NASDAQ Stock Exchange Global Select Market

74.75USD
28 Mar 2017
Change (% chg)

$-0.18 (-0.24%)
Prev Close
$74.93
Open
$74.75
Day's High
$74.75
Day's Low
$74.75
Volume
1,334
Avg. Vol
207,272
52-wk High
$76.24
52-wk Low
$45.90

Latest Key Developments (Source: Significant Developments)

New evidence-based recommendation released from NICE (U.K.) for lateral interbody fusion
Monday, 20 Mar 2017 09:00am EDT 

Nuvasive Inc : New evidence-based recommendation released from NICE (U.K.) for lateral interbody fusion .NICE stated evidence on efficacy for lateral interbody fusion is adequate in quality and quantity.  Full Article

Nuvasive Q4 non-gaap earnings per share $0.53
Thursday, 9 Feb 2017 04:05pm EST 

Nuvasive Inc : Nuvasive reports fourth quarter and full year 2016 financial results . Q4 non-gaap earnings per share $0.53 . Q4 gaap earnings per share $0.11 . Q4 revenue rose 25.9 percent to $271.1 million . Sees 2017 revenue of $1,065 million . Sees 2017 earnings per share of $1.16 . Sees 2017 non-gaap earnings per share of $2.00 .Fy2017 earnings per share view $2.06, revenue view $1.07 billion -- Thomson Reuters I/B/E/S.  Full Article

Nuvasive sees FY 2017 revenue $1.065 bln
Monday, 9 Jan 2017 08:00am EST 

Nuvasive Inc : Sees fy 2017 revenue $1.065 billion . Sees fy 2016 revenue about $956 million . Nuvasive inc - preliminary full year 2016 non-gaap operating profit margin expected to be in line with guidance of 16.0% . Fy2016 revenue view $952.2 million -- Thomson Reuters I/B/E/S . Fy2017 revenue view $1.07 billion -- Thomson Reuters I/B/E/S .Nuvasive inc - expects full year 2017 non-gaap operating profit margin expansion of approximately 100 basis points compared to full year 2016..  Full Article

NuVasive - sees 2016 revenue of approximately $962 mln
Tuesday, 26 Jul 2016 04:02pm EDT 

NuVasive Inc : FY2016 earnings per share view $1.51, revenue view $936.0 million -- Thomson Reuters I/B/E/S . NuVasive reports second quarter 2016 financial results . Q2 non-GAAP earnings per share $0.40 . Q2 GAAP earnings per share $0.57 . Q2 revenue rose 16.4 percent to $236.2 million . Sees 2016 revenue of approximately $962.0 million . Sees 2016 non-GAAP diluted earnings per share of approximately $1.64 .Sees 2016 non-GAAP operating profit margin of approximately 16.0 pct.  Full Article

Nuvasive agrees to settle patent litigation with Medtronic
Thursday, 30 Jun 2016 04:05pm EDT 

Nuvasive Inc : Nuvasive agrees to settle patent litigation with Medtronic . Nuvasive and Medtronic reached agreement on terms for settlement of previously disclosed patent infringement lawsuits . Company and Medtronic intend to enter into a definitive settlement agreement within 15 days . Reached agreement on terms for withdrawal from proceedings in United States patent and trademark office . After settlement agreement, company will make a one-time payment of $45 million to medtronic .Parties will release each other from any and all liabilities arising out of litigation.  Full Article

NuVasive to acquire Biotronic NeuroNetwork
Monday, 6 Jun 2016 04:05pm EDT 

NuVasive Inc : NuVasive to acquire Biotronic NeuroNetwork . Deal for $98 million . Board of directors of both companies have unanimously approved transaction . Deal immediately accretive to non-GAAP diluted earnings, aligned to operating and EBITDA margin expansion . NuVasive expects to fund acquisition with existing cash on hand .NuVasive expects transaction to be significantly accretive in 2017 and beyond.  Full Article

NuVasive Inc announces proposed offering of $550 million of convertible senior notes due 2021
Wednesday, 9 Mar 2016 04:05pm EST 

NuVasive Inc:Announces proposed offering of $550 million of convertible senior notes due 2021.  Full Article

NuVasive to acquire Ellipse Technologies
Tuesday, 5 Jan 2016 04:15pm EST 

NuVasive Inc :To acquire ellipse technologies.Nuvasive will acquire Ellipse for a $380 million upfront cash payment and a potential $30 million milestone payable in 2017.Expects the acquisition to accelerate its revenue growth toward the high-single digit range.Sees deal to be slightly accretive to the company's non-GAAP diluted earnings per share within the first 12 months.Also expects the transaction to support its five-year, double-digit return on invested capital goal".Nuvasive expects to fund the acquisition with existing cash on hand.  Full Article

NuVasive reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Tuesday, 27 Oct 2015 04:05pm EDT 

NuVasive Inc:Sees FY 2015 revenue of approximately $810.0 million.Sees FY 2015 GAAP diluted earnings per share of approximately $1.24 compared to GAAP loss per diluted share of $(0.36) for 2014; versus a prior expectation of $1.18 for 2015.Sees FY 2015 Non-GAAP diluted earnings per share of approximately $1.25, an increase of approximately 86.6% compared to non-GAAP diluted earnings of $0.67 for 2014; versus a prior expectation of $1.17 for 2015.FY 2015 revenue of $813 million and EPS of $1.20 - Thomson Reuters I/B/E/S.  Full Article

NuVasive reaffirms FY 2015 revenue outlook; raises FY 2015 EPS outlook
Tuesday, 28 Jul 2015 04:05pm EDT 

NuVasive Inc:Projects FY 2015 revenue guidance of approximately $810.0 million.Projects FY 2015 GAAP earnings per share of approximately $1.18.Projects FY 2015 Non-GAAP earnings per share of approximately $1.17.FY 2015 revenue of $812 million and EPS of $1.12 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

Photo

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.